Fig. 2: Efficacy outcomes of sitravatinib in combination with nivolumab and ipilimumab.

a Waterfall plot showing the maximum change in the sum of the longest dimensions in each of the 22 patients treated with sitravatinib + nivolumab + ipilimumab. The IMDC risk category, presence or absence of sarcomatoid and/or rhabdoid dedifferentiation, as well as the baseline peripheral blood neutrophil-to-lymphocyte ratio (NLR) for each patient are also shown. b Swimmer plot showing the durability of responses to therapy. The IMDC risk category, presence or absence of sarcomatoid and/or rhabdoid dedifferentiation, and NLR for each patient are also shown. c, d Kaplan-Meier survival curves for progression-free survival (c) and overall survival (d) in all 22 patients treated with sitravatinib + nivolumab + ipilimumab. Dotted lines intersect the survival curve at median (also printed). Shaded blue areas show 95% Hall-Wellner confidence bands. Source data are provided in the Source Data file.